CRBU•benzinga•
Caribou Biosciences Discontinues GALLOP Phase 1 Trial Of CB-010 For Lupus, Reduces Workforce By ~23%, Estimates Cash payments Of $2.5M-$3.5M From Reduction In Force And Prioritization
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 24, 2025 by benzinga